

**2022-001067-27**

**A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA**

## **W06 Ricerca farmaco**

<b>Titolo/oggetto del contratto di sperimentazione</b>	A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
<b>Codice EUDRACT</b>	2022-001067-27
<b>Promotore</b>	Bayer Spa
<b>Codice del protocollo del promotore</b>	20604 (BAY 2433334 Oceanic Stroke)
<b>Data di nullaosta</b>	06-02-2023
<b>Data sottoscrizione del contratto</b>	15-02-2023
<b>Data di chiusura</b>	
<b>Budget</b>	4.190,00
<b>Rimborsi</b>	0,00
<b>Totale</b>	4.190,00
<b>note</b>	
<b>Data ultima modifica</b>	02-03-2023 15:30:52

# Principal investigators

---

**Nome Unità Operativa** Neurologia di Cesena

---

**Nome principal investigator** Marco Longoni

---

**Principal investigator** [Marco Longoni Neurologia di Cesena](#)

---

**CV Principal investigator** [/documenti/W06/20231205/Longoni\\_Marco\\_CV.pdf](#)

---